Abbott Laboratories (ABT)

Debt-to-equity ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	47,664,000	39,796,000	39,318,000	38,810,000	38,603,000	37,481,000	37,174,000	74,219,000	36,686,000	35,675,000	36,490,000	35,399,000	35,802,000	34,422,000	33,800,000	33,562,000	32,784,000	31,386,000	30,578,000	30,218,000
Debt-to-equity ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $47,664,000K
= 0.00

The debt-to-equity ratio of Abbott Laboratories has remained consistently at 0.00 over the past several quarters, indicating that the company's level of debt relative to its equity is negligible. This suggests that Abbott Laboratories has a strong financial position with a minimal reliance on debt to finance its operations. A low debt-to-equity ratio can be viewed positively by investors and creditors as it signifies lower financial risk and greater stability for the company.